W. Akahata

发表

Structural Studies of Chikungunya Virus-Like Particles Complexed with Human Antibodies: Neutralization and Cell-to-Cell Transmission

J. Porta, M. Rossmann, L. F. Ng, 2015, Journal of Virology.

Reassessing therapeutic antibodies for neglected and tropical diseases

D. Carter, W. Akahata, K. Katsuno, 2020, PLoS neglected tropical diseases.

Structural studies of Chikungunya virus maturation

Sadid A. Hasan, M. Rossmann, T. Klose, 2017, Proceedings of the National Academy of Sciences.

Structural Studies of Chikungunya Virus-like Particles

J. Porta, L. F. Ng, Cheng‐I Wang, 2015 .

A VLP vaccine for epidemic Chikungunya virus protects non-human primates against infection

S. Higgs, M. Rossmann, G. Nabel, 2010, Nature Medicine.

Different Vaccine Vectors Delivering the Same Antigen Elicit CD8+ T Cell Responses with Distinct Clonotype and Epitope Specificity1

D. Douek, D. Margulies, G. Nabel, 2009, The Journal of Immunology.

Analysis of evolutionary conservation in CD1d molecules among primates.

T. Miura, C. Hidaka, W. Akahata, 2005, Tissue antigens.

This information is current as Specificity with Distinct Clonotype and Epitope T Cell Responses + Same Antigen Elicit CD 8 Different Vaccine Vectors Delivering the

D. Douek, D. Margulies, G. Nabel, 2009 .

Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial

J. Mascola, T. Pierson, R. Koup, 2014, The Lancet.

Protein Methyltransferase 2 Inhibits NF- (cid:2) B Function and Promotes Apoptosis†

E. Nabel, T. Yoshimoto, G. Nabel, 2006 .

DNA vaccination of macaques by a full-genome simian/human immunodeficiency virus type 1 plasmid chimera that produces non-infectious virus particles.

W. Akahata, H. Akiyama, Hidemi Takahashi, 2003, The Journal of general virology.

DNA vaccination of macaques by a full genome HIV-1 plasmid which produces noninfectious virus particles.

H. Yamamoto, W. Akahata, H. Takahashi, 2000, Virology.

Protein methyltransferase 2 inhibits NF-kappaB function and promotes apoptosis.

E. Nabel, T. Yoshimoto, G. Nabel, 2006, Molecular and cellular biology.

University of Groningen Development of a Highly Protective Combination Monoclonal Antibody Therapy against Chikungunya Virus Pal,

D. Fremont, T. Pierson, M. Diamond, 2013 .

DNA vaccination of macaques by a full-genome SHIV plasmid that has an IL-2 gene and produces non-infectious virus particles.

T. Miura, W. Akahata, N. Saito, 2006, Vaccine.

Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing anchored RBD: a randomised, observer-blind, phase 1 study

K. Kono, Takehiro Yamamoto, W. Akahata, 2022, medRxiv.

University of Groningen Development of a Highly Protective Combination Monoclonal Antibody Therapy against Chikungunya Virus Pal,

D. Fremont, T. Pierson, M. Diamond, 2013 .

An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design

K. Morita, W. Akahata, M. L. Moi, 2017, Journal of Virology.

A Specific Domain of the Chikungunya Virus E2 Protein Regulates Particle Formation in Human Cells: Implications for Alphavirus Vaccine Design

G. Nabel, W. Akahata, 2012, Journal of Virology.

A virus-like particle vaccine prevents equine encephalitis virus infection in nonhuman primates

U. Baxa, J. Mascola, S. Higgs, 2019, Science Translational Medicine.

Protein Methyltransferase 2 Inhibits NF-κB Function and Promotes Apoptosis

E. Nabel, T. Yoshimoto, G. Nabel, 2006, Molecular and Cellular Biology.

Mutational analysis of two zinc-finger motifs in the nucleocapsid protein of simian immunodeficiency virus mac239.

W. Akahata, E. Ido, M. Hayami, 2003, The Journal of general virology.

Structural analyses at pseudo atomic resolution of Chikungunya virus and antibodies show mechanisms of neutralization

M. Diamond, M. Rossmann, G. Nabel, 2013, eLife.

Development of a Novel Virus-Like Particle Vaccine Platform That Mimics the Immature Form of Alphavirus

M. Rossmann, T. Aoshi, W. Akahata, 2017, Clinical and Vaccine Immunology.

Cryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activity

J. Porta, M. Diamond, S. Austin, 2015, Proceedings of the National Academy of Sciences.

Construction and in vivo infection of a new simian/human immunodeficiency virus chimera containing the reverse transcriptase gene and the 3' half of the genomic region of human immunodeficiency virus type 1.

T. Miura, W. Akahata, H. Akiyama, 2003, The Journal of general virology.

saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern

M. R. Hassett, T. Fukuhara, Tomokazu Tamura, 2023, Nature communications.

Sequential analysis of apoptosis induction in peripheral blood mononuclear cells and lymph nodes in the early phase of pathogenic and nonpathogenic SIVmac infection.

S. Yonehara, J. Imanishi, W. Akahata, 1999, AIDS research and human retroviruses.

Comparative Immunogenicity of Human Immunodeficiency Virus Particles and Corresponding Polypeptides in a DNA Vaccine

G. Nabel, W. Akahata, Zhi-yong Yang, 2005, Journal of Virology.

Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: A randomized, observer-blind phase 1 study

T. Fukuhara, Tomokazu Tamura, W. Akahata, 2023, Cell Reports Medicine.

Incorporation of 5 methylcytidine alleviates innate immune response to self-amplifying RNA vaccine

W. Akahata, H. Akiyama, S. Gummuluru, 2023, bioRxiv.

Development of a Highly Protective Combination Monoclonal Antibody Therapy against Chikungunya Virus

D. Fremont, T. Pierson, G. Nabel, 2013, PLoS pathogens.